Literature DB >> 2061960

Urinary cotinine measurement in patients with Buerger's disease--effects of active and passive smoking on the disease process.

M Matsushita1, S Shionoya, T Matsumoto.   

Abstract

Although Buerger's disease is known to be closely related to smoking, no objective analysis of the smoke-associated problems has been performed. In this study, cotinine, the major metabolite of nicotine, was used as a sensitive marker to measure levels of active smoking and the exposure of nonsmokers to tobacco smoke because it has a relatively long half-life and because cotinine levels can be determined by noninvasive means in urine. According to urinary cotinine levels, 40 patients with Buerger's disease were classified as (1) smokers: those with urinary cotinine levels above 50 ng/mg creatinine; (2) passive smokers: those with levels between 10 and 50 ng/mg creatinine; and (3) nonsmokers who did not experience noticeable passive smoking: those with levels below 10 ng/mg creatinine. There were 10 smokers, 9 passive smokers, and 21 nonsmokers. The course of the disease, after the initial treatment at our hospital, was studied retrospectively. Seven of the 10 smokers, none of the 9 passive smokers, and 4 of the 21 nonsmokers experienced aggravation of the disease. Of the four nonsmokers who experienced aggravation, three had still been smokers and one had been exposed to tobacco smoke in the workplace at the time of relapse. There was a significant difference in the aggravation rate between the smokers' group and the other two groups. Among the smokers, the seven patients whose conditions worsened showed significantly higher cotinine levels than the three remaining patients who were in the stage of remission.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2061960

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  9 in total

1.  Thromboangiitis Obliterans (Buerger's Disease).

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-06

Review 2.  Thromboangiitis obliterans. An update on Buerger's disease.

Authors:  A Szuba; J P Cooke
Journal:  West J Med       Date:  1998-04

3.  Fate of ischemic limbs in patients with Buerger's disease based on our 30-year experience: does smoking have a definitive impact on the late loss of limbs?

Authors:  Masayuki Sugimoto; Hiroki Miyachi; Hirofumi Morimae; Akio Kodama; Hiroshi Narita; Hiroshi Banno; Kiyohito Yamamoto; Kimihiro Komori
Journal:  Surg Today       Date:  2014-04-26       Impact factor: 2.549

4.  The influence of smoking on success of tympanoplasty measured by serum cotinine analysis.

Authors:  M Zafer Uguz; Kazim Onal; K Cagdas Kazikdas; Aytul Onal
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-10-18       Impact factor: 2.503

5.  Association Between Three SNPs and Thromboangiitis Obliterans in Xinjiang Uyghur Population.

Authors:  Zhen-Feng Shi; Qing-Bo Fang; Sai Limu; Tang Jiareke; Xiao-Hu Ge
Journal:  Genet Test Mol Biomarkers       Date:  2016-02-01

Review 6.  Thromboangiitis Obliterans (Buerger's Disease)-Current Practices.

Authors:  Abhishek Vijayakumar; Rahul Tiwari; Vinod Kumar Prabhuswamy
Journal:  Int J Inflam       Date:  2013-09-11

7.  The Imbalance among Oxidative Biomarkers and Antioxidant Defense Systems in Thromboangiitis Obliterans (Winiwarter-Buerger Disease).

Authors:  Hiva Sharebiani; Bahare Fazeli; Rosanna Maniscalco; Daniela Ligi; Ferdinando Mannello
Journal:  J Clin Med       Date:  2020-04-07       Impact factor: 4.241

8.  Phase IV postmarketing surveillance study shows continued efficacy and safety of Stempeucel in patients with critical limb ischemia due to Buerger's disease.

Authors:  Pawan Kumar Gupta; Santanu Dutta; Sanjay Kala; Muralikrishna Nekkanti; Sanjay C Desai; Subhendu S Mahapatra; Anita Dhar; Radhakrishnan Raju; Rajkumar M; Arunanshu Behera; Shivashankar P; N S Raviraja; Pachaiyappan Viswanathan; Mithun Chandrashekar; Charan Thej; Prasanth K V; Jijy Abraham; Hema Boggarapu; K Udaykumar
Journal:  Stem Cells Transl Med       Date:  2021-09-13       Impact factor: 6.940

9.  Stem cell therapy for treatment of thromboangiitis obliterans (Buerger's disease).

Authors:  Daniel G Cacione; Frederico do Carmo Novaes; Daniel H Moreno
Journal:  Cochrane Database Syst Rev       Date:  2018-10-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.